BiVictriX Therapeutics PLC Result of General Meeting (7024I)
August 08 2023 - 11:18AM
UK Regulatory
TIDMBVX
RNS Number : 7024I
BiVictriX Therapeutics PLC
08 August 2023
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
ARTICLE 7 OF THE EU REGULATION 596/2014 AS IT FORMS PART OF THE UK
LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").
UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY
INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE
PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company")
Result of General Meeting
Completion of Fundraise
Total Voting Rights
Alderley Park, 8 August 2023 - BiVictriX Therapeutics plc (AIM:
BVX), an emerging biotechnology company applying a differentiated
approach to develop next-generation cancer therapies with
substantially improved cancer cell selectivity and anti-cancer
activity, announces that at the Company's General Meeting held
today at 11:00 a.m. at the Company's registered office, Mereside
Alderly Park, Alderly Edge, Manchester SK10 4TG, all resolutions
were duly passed. Further details of each of the resolutions are
set out in the Circular and Notice of Meeting, which was sent to
shareholders on 20 July 2023 (the "Circular").
Details of proxy votes received are summarised below:
R esolution V otes Votes Against Discretionary Withheld
For Votes
Ordinary Resolution
In accordance with sec ti
on 551 of the Companies
Act 2006, the directors
of the Company in addi ti
on to all previous authori
ti es granted to the Directors,
be generally and uncondi
ti onally authorised to
exercise all the powers
of the Company to allot
shares in the Company, and
grant rights to subscribe
for or convert any securi
ti es into shares in the
Company, up to an aggregate
nominal amount of GBP164,108.87
(within the meaning of sec
ti ons 551(3) and (6) of
the said Act), in connec
ti on with the Fundraise
detailed in the Circular. 20,010,176 1 - -
----------- -------------- -------------- ---------
Special Resolution
In accordance with sec ti
on 570 of the Act, the Directors
be generally empowered to
allot equity securi ti es
(as de fi ned in sec ti
on 560(1) of the Act) which
are the subject of the authority
conferred by resolu ti on
1 as if sec ti on 561 of
the Act did not apply to
such allotment, provided
that this power shall be
limited to the allotment
of equity securi ti es up
to an aggregate nominal
amount of GBP164,108.87,
in connec ti on with the
Fundraise detailed in the
Circular. 20,010,176 1 - -
----------- -------------- -------------- ---------
Completion of Fundraise
The Resolutions were necessary to implement the Fundraise to
raise a total of GBP2.1 million (before expenses), as announced by
the Company on 19 July 2023.
Following the passing of the Resolutions, the Company has
allotted (subject only to Admission) the Placing Shares and the
Subscription Shares with new and existing investors (the "New
Ordinary Shares"). The New Ordinary Shares will rank pari passu
with the Company's Existing Ordinary Shares.
Admission to AIM and Total Voting Rights
Application has been made for the Admission of 16,410,887 New
Ordinary Shares. It is expected that Admission will take place and
that trading in the New Ordinary Shares will commence, at 8.00 a.m.
on 10 August 2023.
Following Admission, the Company's issued and fully paid share
capital will consist of 82,526,088 Ordinary Shares. The Company has
no Ordinary Shares in treasury. As such, the total number of voting
rights in the Company will be 82,526,088 Ordinary Shares. Following
Admission, this number may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest, or a change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
Note
This announcement should be read in conjunction with the full
text of the Circular sent to shareholders on 20 July 2023 in
connection with the Fundraise. Capitalised terms used but not
otherwise defined in this announcement bear the meanings ascribed
to them in the Circular.
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non-Executive Chairman Email: info@bivictrix.com
SP Angel Corporate Finance LLP (NOMAD Tel: +44 (0) 20 3470
and Broker) 0470
David Hignell, Kasia Brzozowska (Corporate
Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886
Broker) 2500
Rupert Dearden/Freddy Crossley/Emma
Earl
Consilium Strategic Communications
Mary-Jane Elliott, Namrata Taak, Tel: +44 (0) 20 3709 5700
Max Bennett, Emmalee Hoppe Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX (AIM: BVX) is an emerging biotechnology company
leveraging clinical experience and its proprietary discovery engine
to advance a new class of highly cancer-selective, next-generation
precision cancer therapies in one of the fastest-growing markets in
oncology. BiVictriX's first-in-class Bi-Cygni(R) Antibody Drug
Conjugates (ADCs) combine superior efficacy with substantially
improved cancer-selectivity and safety to provide opportunities for
prolonged dosing and greater efficacy in the clinic. The Company is
advancing its pipeline to deliver the future of cancer care across
a broad range of haematological and solid cancer indications in
areas of high unmet medical need.
Find out more at www.bivictrix.com and connect with us on
LinkedIn and Twitter @BiVictriX .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMQVLFBXVLFBBE
(END) Dow Jones Newswires
August 08, 2023 12:18 ET (16:18 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Sep 2023 to Sep 2024